Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

US6903101B1 · kind B1 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Jacques Dumas · Neuilly-Plaisance, FR
• Stephen Boyer · Fairfield, US
• Teddy Kite Joe · New York, US
• Holia Hatoum-Mokdad · Hamden, US
• Harold Kluender · Hartland, US
• Wendy Lee · Hamden, US
• Dhanapalan Nagarathnam · Bethany, US
• Robert Sibley · North Haven, US
• Ning Su · Hamden, US

Key dates

• Filing date: Aug 10, 2000
• Grant date: Jun 7, 2005
• Expiry date: Nov 3, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Substituted and Fused pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1 and R2 may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.